Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-73.91M |
| Operating Margin | 0.00% |
| Return on Equity | -66.00% |
| Return on Assets | -40.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.42 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $21.88M |
| Float | $11.01M |
| % Insiders | 15.77% |
| % Institutions | 52.58% |
Volatility is currently expanding
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
BENSALEM, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026 inclusive (the “Class Period”).
A securities class action alleges Aardvark Therapeutics overstated the clinical, regulatory, and commercial prospects of ARD-101 while representing the drug as nearly free of systemic exposure, before a trial pause and FDA clinical hold erased most of the stock's value. NEW YORK, Sept.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the "IPO" or "Offering"); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aardvark (AARD) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and certain officers and directors.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark's February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
A securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold A securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold
LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AARD and any ticker you trade — then tracks every position and per-strategy win rate.
